- Parent companies: Genzyme Corporation and Bayer HealthCare Pharmaceuticals.
- Administered via once-yearly cycles of intravenous infusions (other dosing and methods of administration have been used).
- Used to treat Leukemia; also studied in the treatment of rheumatoid arthritis.
- Targets certain T-cells, B-cells, and macrophages; results in a depletion of T-cells.
- CAMMS223 Phase 2 study compared Campath to high-dose Rebif in an open-label study with RRMS patients.
- Interim analysis from CAMMS223 showed a 75-percent reduction in risk of relapse and a 65-percent reduction in progression to significant disability in those treated with Campath.
- Dosing was suspended in September 2005 when a few patients developed a serious bleeding condition from decreased platelets in the blood, resulting in one fatality.
- Patients need to be monitored closely due to risk of significant toxicities.
- Apparently more effective when given in RRMS versus SPMS.